Portfolio Holdings Detail for ISIN IE00BF4RFH31
Stock Name / FundiShares MSCI World Small Cap UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares III Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300PZLRJB7M8H1057
ETF TickerWSML(USD) LSE
ETF TickerWLDS(GBP) LSE
ETF TickerIUSN(EUR) F
ETF TickerIUSN.DE(EUR) CXE
ETF TickerWLDS.LS(GBP) CXE
ETF TickerWSML.LS(USD) CXE
ETF TickerWSML.L(GBP) LSE
ETF TickerWLDS.L(GBP) LSE

Holdings detail for NTLA

Stock NameIntellia Therapeutics Inc
TickerNTLA(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS45826J1051
LEI5493002T5BCPE5DZC723

Show aggregate NTLA holdings

News associated with NTLA

Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus
Even in a choppy market, Zacks' strategies are spotlighting winners like Oracle, Intellia, and Pharming Group, proving the value of a disciplined, research-driven approach. - 2025-09-02 10:03:00
Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Up After Insider Buying Activity
Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) shares gapped up before the market opened on Monday following insider buying activity. The stock had previously closed at $10.52, but opened at $11.07. Intellia Therapeutics shares last traded at $11.34, with a volume of 1,615,773 shares trading hands. Specifically, Director William J. Chase purchased 100,000 shares […] - 2025-08-27 02:18:42
Mitsubishi UFJ Asset Management Co. Ltd. Boosts Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 24.1% in the 1st quarter, HoldingsChannel reports. The firm owned 21,458 shares of the company’s stock after buying an additional 4,165 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Intellia Therapeutics were worth […] - 2025-08-15 05:44:58
Take the Zacks Approach to Beat the Markets: Digi Power X, RF Industries & Starbucks in Focus
Zacks spotlights Digi Power X, RF Industries and Starbucks as standout gainers amid market volatility and economic uncertainty. - 2025-08-11 08:43:00
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Purchased by XTX Topco Ltd
XTX Topco Ltd boosted its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 84.2% in the 1st quarter, HoldingsChannel reports. The firm owned 80,897 shares of the company’s stock after purchasing an additional 36,989 shares during the period. XTX Topco Ltd’s holdings in Intellia Therapeutics were worth $575,000 at the end of the […] - 2025-08-07 04:58:54
Take the Zacks Approach to Beat the Markets: AngloGold Ashanti, Caterpillar & Hershey in Focus
AU, CAT and HSY are standing out as Zacks' high-conviction picks, with each posting double-digit gains in recent weeks. - 2025-07-28 09:41:00
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Rating of “Moderate Buy” from Analysts
Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) have earned an average recommendation of “Moderate Buy” from the twenty ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, twelve have given a buy rating […] - 2025-07-24 05:11:08
Commit To Buy Intellia Therapeutics At $10, Earn 28.5% Using Options
Investors considering a purchase of Intellia Therapeutics Inc (Symbol: NTLA) stock, but tentative about paying the going market price of $13.21/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in - 2025-07-21 12:36:47
Alps Advisors Inc. Sells 5,030 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Alps Advisors Inc. trimmed its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 6.1% in the 1st quarter, Holdings Channel reports. The firm owned 77,328 shares of the company’s stock after selling 5,030 shares during the quarter. Alps Advisors Inc.’s holdings in Intellia Therapeutics were worth $550,000 at the end of […] - 2025-07-15 06:25:51
Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus
Zacks' model upgrades drove major gains for Amarin, Mogo and 3M, even as broader markets wobbled on tariff fears. - 2025-07-14 10:06:00
Wealth Enhancement Advisory Services LLC Makes New Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Wealth Enhancement Advisory Services LLC purchased a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 13,789 shares of the company’s stock, valued at approximately $98,000. Several other large investors also recently modified […] - 2025-07-11 04:16:51
Brokerages Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target at $33.37
Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) has been given an average rating of “Moderate Buy” by the twenty research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has given […] - 2025-07-02 03:14:50
SG Americas Securities LLC Sells 3,401 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
SG Americas Securities LLC lessened its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 7.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 41,437 shares of the company’s stock after selling 3,401 shares during the quarter. SG Americas Securities LLC’s […] - 2025-06-27 04:21:01
Rhumbline Advisers Reduces Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Rhumbline Advisers trimmed its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 5.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 156,838 shares of the company’s stock after selling 9,410 shares during the quarter. Rhumbline Advisers’ holdings in […] - 2025-06-20 04:22:49
GAMMA Investing LLC Raises Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
GAMMA Investing LLC increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 1,961.2% during the first quarter, Holdings Channel.com reports. The firm owned 7,544 shares of the company’s stock after acquiring an additional 7,178 shares during the quarter. GAMMA Investing LLC’s holdings in Intellia Therapeutics were worth $540,000 at the end of […] - 2025-06-19 04:08:57
Intellia Therapeutics (NASDAQ:NTLA) Earns Buy Rating from HC Wainwright
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $30.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 213.15% from the company’s current […] - 2025-06-18 02:22:53
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of “Moderate Buy” by Brokerages
Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) has been given an average rating of “Moderate Buy” by the twenty-one ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, thirteen have issued a buy rating and one […] - 2025-06-04 04:52:47
Nuveen Asset Management LLC Sells 105,170 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Nuveen Asset Management LLC trimmed its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 28.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 260,697 shares of the company’s stock after selling 105,170 shares during the quarter. Nuveen Asset Management LLC’s […] - 2025-06-03 06:04:57
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 5.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 483,185 shares of the company’s […] - 2025-06-03 05:13:02
ProShare Advisors LLC Has $389,000 Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
ProShare Advisors LLC grew its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 38.0% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 33,404 shares of the company’s stock after acquiring an additional 9,196 shares during the period. ProShare Advisors LLC’s holdings in Intellia Therapeutics were worth $389,000 at the end […] - 2025-05-29 05:04:57
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 15,888 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 7.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 227,255 shares of the company’s stock after buying an additional 15,888 shares during the period. MIRAE […] - 2025-05-21 05:40:53
BNP Paribas Financial Markets Has $5.11 Million Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
BNP Paribas Financial Markets increased its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 78.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 438,458 shares of the company’s stock after purchasing an additional 192,096 shares during […] - 2025-05-14 06:12:50
Guggenheim Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $45.00
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price target cut by investment analysts at Guggenheim from $55.00 to $45.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price target indicates a potential upside of 440.87% from the stock’s previous close. […] - 2025-05-14 02:56:48
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $36.47 Consensus Target Price from Brokerages
Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty-one research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, thirteen have assigned a buy recommendation […] - 2025-05-13 02:44:49
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Holdings Cut by Voya Investment Management LLC
Voya Investment Management LLC lessened its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 7.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 28,829 shares of the company’s stock after selling 2,213 shares during the period. Voya Investment Management LLC’s holdings in Intellia […] - 2025-05-12 05:26:58
Citigroup Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $10.00
Intellia Therapeutics (NASDAQ:NTLA – Free Report) had its price objective reduced by Citigroup from $14.00 to $10.00 in a research note released on Friday,Benzinga reports. They currently have a neutral rating on the stock. A number of other equities analysts have also commented on the stock. Wedbush restated a “neutral” rating and issued a $10.00 […] - 2025-05-12 04:26:47
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Mariner LLC
Mariner LLC decreased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 14.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,820 shares of the company’s stock after selling 2,496 shares during the quarter. Mariner LLC’s holdings in Intellia Therapeutics were worth […] - 2025-05-08 04:38:44
Dimensional Fund Advisors LP Purchases 528,962 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Dimensional Fund Advisors LP increased its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 36.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,976,212 shares of the company’s stock after purchasing an additional 528,962 shares during the quarter. […] - 2025-05-07 05:26:54
MetLife Investment Management LLC Buys 3,491 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
MetLife Investment Management LLC boosted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 6.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 59,187 shares of the company’s stock after purchasing an additional 3,491 shares during the period. […] - 2025-05-05 05:22:56
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood's investing style is bouncing back into fancy. The co-founder, CEO, and investment manager of Ark Invest is winning again. Her most popular exchange-traded fund has risen 6% over the past month, a welcome contrast to the flat overall market in that time. Her 14% retur - 2025-04-30 11:15:00

iShares MSCI World Small Cap UCITS ETF USD (Acc) NTLA holdings

DateNumber of NTLA Shares HeldBase Market Value of NTLA SharesLocal Market Value of NTLA SharesChange in NTLA Shares HeldChange in NTLA Base ValueCurrent Price per NTLA Share HeldPrevious Price per NTLA Share Held
2026-01-23 (Friday)78,026USD 1,141,520NTLA holding decreased by -99093USD 1,141,5200USD -99,093 USD 14.63 USD 15.9
2026-01-22 (Thursday)78,026USD 1,240,613NTLA holding increased by 145908USD 1,240,6130USD 145,908 USD 15.9 USD 14.03
2026-01-21 (Wednesday)78,026USD 1,094,705NTLA holding increased by 93631USD 1,094,7050USD 93,631 USD 14.03 USD 12.83
2026-01-20 (Tuesday)78,026NTLA holding increased by 306USD 1,001,074NTLA holding increased by 29574USD 1,001,074306USD 29,574 USD 12.83 USD 12.5
2026-01-19 (Monday)77,720USD 971,500USD 971,5000USD 0 USD 12.5 USD 12.5
2026-01-16 (Friday)77,720USD 971,500NTLA holding increased by 48964USD 971,5000USD 48,964 USD 12.5 USD 11.87
2026-01-15 (Thursday)77,720USD 922,536NTLA holding decreased by -11658USD 922,5360USD -11,658 USD 11.87 USD 12.02
2026-01-14 (Wednesday)77,720USD 934,194NTLA holding increased by 21761USD 934,1940USD 21,761 USD 12.02 USD 11.74
2026-01-13 (Tuesday)77,720USD 912,433NTLA holding increased by 24093USD 912,4330USD 24,093 USD 11.74 USD 11.43
2026-01-12 (Monday)77,720USD 888,340NTLA holding increased by 81606USD 888,3400USD 81,606 USD 11.43 USD 10.38
2026-01-09 (Friday)77,720USD 806,734NTLA holding decreased by -10880USD 806,7340USD -10,880 USD 10.38 USD 10.52
2026-01-08 (Thursday)77,720NTLA holding increased by 155USD 817,614NTLA holding increased by 31881USD 817,614155USD 31,881 USD 10.52 USD 10.13
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of NTLA by Blackrock for IE00BF4RFH31

Show aggregate share trades of NTLA

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2026-01-20BUY30613.16811.930 12.054USD 3,688 11.56
2026-01-08BUY15510.73710.320 10.362USD 1,606 11.55
2025-12-16BUY4779.2608.910 8.945USD 4,267 11.69
2025-12-12BUY7909.6809.020 9.086USD 7,178 11.72
2025-12-01SELL-2,1848.8908.395 8.445USD -18,443 11.82 Profit of 7,366 on sale
2025-11-26SELL-1578.6308.400 8.423USD -1,322 11.86 Profit of 539 on sale
2025-11-26SELL-1578.6308.400 8.423USD -1,322 11.86 Profit of 539 on sale
2025-11-20BUY5258.8807.950 8.043USD 4,223 11.92
2025-11-19BUY5,1608.6308.200 8.243USD 42,534 11.94
2025-11-14SELL-6208.8808.380 8.430USD -5,227 11.99 Profit of 2,206 on sale
2025-10-29BUY30013.12014.000 13.912USD 4,174 12.02
2025-10-21BUY58826.97027.857 27.768USD 16,328 11.72
2025-10-07BUY29820.44020.850 20.809USD 6,201 11.53
2025-09-08SELL-60811.84012.300 12.254USD -7,450 11.23 Loss of -620 on sale
2025-08-15BUY30410.99011.305 11.274USD 3,427 11.24
2025-08-07BUY90611.46011.535 11.527USD 10,444 11.24
2025-07-29BUY30012.50013.190 13.121USD 3,936 11.21
2025-07-14BUY60811.95012.120 12.103USD 7,359 11.16
2025-06-30BUY6169.3809.675 9.646USD 5,942 11.16
2025-06-25BUY9249.5609.660 9.650USD 8,917 11.19
2025-06-20SELL-1559.2009.943 9.869USD -1,530 11.23 Profit of 210 on sale
2025-06-12SELL-1,2648.3508.445 8.435USD -10,662 11.31 Profit of 3,635 on sale
2025-06-02BUY4807.1607.590 7.547USD 3,623 11.50
2025-05-28BUY3129.6609.785 9.772USD 3,049 11.57
2025-05-14BUY1567.8808.544 8.478USD 1,323 11.77
2025-05-13BUY3128.3208.750 8.707USD 2,717 11.80
2025-05-07BUY4687.2907.498 7.477USD 3,499 11.92
2025-04-28BUY1558.4808.835 8.799USD 1,364 12.13
2025-04-16BUY2,0546.8607.270 7.229USD 14,848 12.44
2025-04-14BUY3167.5007.670 7.653USD 2,418 12.53
2025-04-08SELL-3206.2807.030 6.955USD -2,226 12.75 Profit of 1,854 on sale
2025-04-04SELL-3246.6306.910 6.882USD -2,230 12.87 Profit of 1,940 on sale
2025-03-28BUY1,5708.0708.430 8.394USD 13,179 13.09
2025-03-12SELL-3129.6209.660 9.656USD -3,013 13.65 Profit of 1,247 on sale
2025-03-04SELL-3109.0959.530 9.486USD -2,941 13.91 Profit of 1,370 on sale
2025-02-26SELL-61610.80011.100 11.070USD -6,819 14.09 Profit of 1,861 on sale
2025-02-13BUY1609.6409.715 9.708USD 1,553 14.46
2025-02-12BUY6369.5109.580 9.573USD 6,088 14.53
2025-01-27BUY15510.55010.774 10.752USD 1,666 15.50
2025-01-23BUY15611.29011.360 11.353USD 1,771 15.67
2024-12-09BUY5,54414.62015.295 15.228USD 84,421 15.89
2024-12-04BUY30414.49015.040 14.985USD 4,555 15.99
2024-12-03BUY45614.65015.700 15.595USD 7,111 16.02
2024-11-19BUY91814.13014.260 14.247USD 13,079 16.50
2024-11-18BUY30414.17015.200 15.097USD 4,589 16.57
2024-11-12BUY60016.65017.240 17.181USD 10,309 16.57
2024-11-11BUY15117.50017.830 17.797USD 2,687 16.50
2024-11-11BUY15117.50017.830 17.797USD 2,687 16.50
2024-11-07BUY75016.00017.150 17.035USD 12,776 16.52
2024-11-07BUY75016.00017.150 17.035USD 12,776 16.52
2024-10-23BUY29419.94021.170 21.047USD 6,188 20.88
2024-10-23BUY29419.94021.170 21.047USD 6,188 20.88
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of NTLA

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-192,488,21625,9124,783,02652.0%
2025-09-183,275,17025,8088,092,76240.5%
2025-09-171,795,7605,8053,049,64858.9%
2025-09-16882,7801,1103,448,05925.6%
2025-09-15742,270871,788,36241.5%
2025-09-12722,3354001,382,22152.3%
2025-09-11875,8647,0541,871,68146.8%
2025-09-101,504,2395,7622,264,60066.4%
2025-09-091,403,87413,3412,383,47558.9%
2025-09-08918,1171381,520,95960.4%
2025-09-051,009,1372,1442,403,55642.0%
2025-09-04673,3557,2371,306,22151.5%
2025-09-031,086,3501,5832,619,35341.5%
2025-09-02670,3971,1671,423,04747.1%
2025-08-29537,4682,1001,149,46646.8%
2025-08-28861,12701,850,84046.5%
2025-08-27562,88531,151,55148.9%
2025-08-26587,4712181,339,28243.9%
2025-08-25944,6762,5342,848,39633.2%
2025-08-22471,9941,0101,271,51237.1%
2025-08-21664,42001,098,36860.5%
2025-08-20717,6611751,330,49753.9%
2025-08-191,307,3613,2091,995,17365.5%
2025-08-18749,6934,8521,667,25045.0%
2025-08-15929,7746292,294,40440.5%
2025-08-141,573,7209482,631,09059.8%
2025-08-131,587,3051,2572,999,67352.9%
2025-08-12943,0332,9121,526,98161.8%
2025-08-11673,8925961,352,23349.8%
2025-08-081,135,0265,9191,684,23567.4%
2025-08-07930,5373051,823,81751.0%
2025-08-06841,9404551,751,62648.1%
2025-08-05766,4981531,479,64951.8%
2025-08-04806,2139811,511,50753.3%
2025-08-011,211,5522,1212,016,62260.1%
2025-07-311,494,6036,2362,951,39850.6%
2025-07-30876,6011,3001,994,39444.0%
2025-07-29903,3802,8932,182,94441.4%
2025-07-28602,1541,7131,783,81433.8%
2025-07-25830,629114,1572,043,99840.6%
2025-07-241,624,048106,0133,581,47745.3%
2025-07-231,590,06513,5703,054,68352.1%
2025-07-22899,4603,2991,834,33049.0%
2025-07-211,344,5376,3712,694,80349.9%
2025-07-18725,1296321,386,25452.3%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.


Copyright Market Footprint Ltd. Privacy Policy